UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

The median overall survival with pembrolizumab/olaparib was 25.1 months vs 23.4 months with pembrolizumab plus chemotherapy.

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Trastuzumab deruxtecan outperformed investigators choice of therapy, in terms of safety, among patients with HER2-Low Metastatic Breast Cancer.

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.

Patients with unresectable pancreatic cancers and cholangiocarcinoma face poor prognoses, but systemic treatment continues to evolve.

Sarah Donahue, MPH, AOCNP, cochair of the 40th Annual Miami Breast Cancer Conference nursing track, discusses the biggest updates in breast cancer from 2022.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, highlights her top takeaways from the 64th American Society of Hematology Annual Meeting and Exposition.

During the 40th Annual Chemotherapy Foundation Symposium®, Hope S. Rugo, MD, FASCO, outlined key priorities for the future of breast cancer research.

HER2-directed antibody-drug conjugates (ADCs) play an important role in the treatment of breast and gastric cancer.

At the 2022 ASCO Quality Care Symposium, an adverse event analysis showed that abemaciclib has a manageable safety profile and that dose reductions may be a key aspect of appropriate symptom management.

In a presentation at the 2022 Oncology Nursing Society Bridge, Stephany L. Rodriguez, RN, MS, NP, discussed the later effects associated with hematopoietic stem cell transplant and how to manage them.

In this episode of “The Vitals,” Christine Miaskowski, PhD, RN, discusses research showcasing that adult patients receiving either a platinum-based chemotherapy, taxane alone, or a combined regimen of platinum- and taxane-based treatment may be at risk of hearing loss.

Sacituzumab govitecan may represent a promising option for patients with endocrine resistant, hormone receptor–positive/HER2-negative metastatic breast cancer, according to updated findings from the phase 3 TROPiCs-02 study.

In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.

Hearing loss for cancer survivors is largely underreported, but once identified, is easily treatable, according to Christine Miaskowski, PhD, RN.

Sarah Donahue, MPH, NP, AOCNP, explains the trial design of the pivotal DESTINY-Breast04 trial and discusses how the promising performance of trastuzumab deruxtecan might impact patients with unresectable or metastatic HER2-low breast cancer.

Ribociclib was associated with significantly favorable symptom-related quality of life scores compared with abemaciclib among women with hormone receptor–positive, HER2-negative advanced breast cancer.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, presents a case study of a patient receiving chemotherapy for osteosarcoma who begins experiencing shortness of breath.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, recounts key nursing considerations with targeted therapy for chronic lymphocytic leukemia, and third-line diffuse large b-cell lymphoma options.

Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Unrelieved stress may contribute to cancer-related cognitive impairment and anxiety in patients undergoing chemotherapy.

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses third-line treatment options for patients with diffuse large b-cell lymphoma.

Laura Zitella, MS, RN, ACNP-BC, AOCN, reviews a case study where a 52-year-old female patient with metastatic colorectal carcinoma begins experiencing diffuse abdominal pain.

Patients with hormone receptor–positive, HER2-negative metastatic breast cancer achieved statistically significantly improvements in progression-free survival after receiving sacituzumab govitecan.

The nurse-specific track returns to the Miami Breast Cancer Conference® agenda for a second year in 2022.

A post-hoc analysis of 2 studies revealed that patients with advanced prostate cancer receiving apalutamide reported positive wellbeing scores during treatment.

Seventy-three percent of advanced practice providers reported that they are interested in becoming more involved with clinical trials.

Sarah Donahue, MPH, AOCNP, shares what drew her to oncology, the daily challenges she faces as a nurse practitioner, and her advice to new oncology nurses on how to overcome those barriers.

Thomas G. Martin, MD, discusses the results of the IKEMA study and the future of isatuximab combination.

BCMA-directed CAR T-cell therapy is drastically changing the multiple myeloma treatment landscape.